NCCN Flash Updates: NCCN Templates® for Non-Small Cell Lung Cancer
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Non-Small Cell Lung Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v2.2021.
- The Title has been updated on the following NCCN Templates® to be consistent with our standard naming conventions:
- NSC33: DOCEtaxel/CISplatin
- NSC41: CARBOplatin/Etoposide
- NSC52: PEMEtrexed/CARBOplatin with Concurrent Radiation
- NSC53: PEMEtrexed/CISplatin with Concurrent Radiation
- NSC62: Ramucirumab + DOCEtaxel
- NSC73: DOCEtaxel/CISplatin
- NSC76: Pembrolizumab + PEMEtrexed/CARBOplatin
- NSC83: PEMEtrexed/CARBOplatin
- NSC84: Pembrolizumab + PEMEtrexed/CISplatin
- NCS85a: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin Course
- NSC85b: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab Maintenance Course
- NSC86: Pembrolizumab + PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC88: Pembrolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
- NSC104: Nivolumab + Ipilimumab + PEMEtrexed/CARBOplatin
- NSC105: Nivolumab + Ipilimumab + PEMEtrexed/CISplatin
- The following NCCN Template has been deleted. The content (including dosing, indications, and references) has been combined with the following current template in the library:
- NSC70: Atezolizumab is now part of NSC103: Atezolizumab
- References have been updated for the following templates:
- NSC58: CISplatin/Etoposide with Concurrent Radiation
- NSC64: Pembrolizumab
- NSC66: Osimertinib
- NSC79: Vemurafenib
- NSC80: Durvalumab
- NSC92: Lorlatinib
- NSC93: Larotrectinib
- NSC94: Entrectinib
- NSC99: Selpercatinib
- NSC102: Capmatinib
- NSC103: Atezolizumab
- Changes to the Indication section have been made on the following templates:
- NSC17: PACLitaxel
- NSC18: DOCEtaxel
- NSC20: Gemcitabine
- NSC26: PEMEtrexed
- NSC28: Gemcitabine/CARBOplatin
- NSC30: DOCEtaxel/CARBOplatin
- NSC31: Gemcitabine/DOCEtaxel
- NSC36: CISplatin/Etoposide
- NSC38: PACLitaxel/CISplatin
- NSC41: CARBOplatin/Etoposide
- NSC44: PACLitaxel/CARBOplatin + Bevacizumab
- NSC48: Albumin-bound PACLitaxel
- NSC49: PEMEtrexed/CARBOplatin
- NSC54: Albumin-bound PACLitaxel/CARBOplatin
- NSC55: PEMEtrexed/CARBOplatin + Bevacizumab
- NSC57: VinORELBine/Gemcitabine
- NSC59: PEMEtrexed/CISplatin + Bevacizumab
- NSC61: Ceritinib
- NSC64: Pembrolizumab
- NSC66: Osimertinib
- NSC69: Afatinib + Cetuximab
- NSC71: PACLitaxel/CARBOplatin
- NSC72: Gemcitabine/CISplatin
- NSC73: DOCEtaxel/CISplatin
- NSC74: PEMEtrexed/CISplatin
- NSC76: Pembrolizumab + PEMEtrexed/CARBOplatin
- NSC80: Durvalumab
- NSC84: Pembrolizumab + PEMEtrexed/CISplatin
- NSC85a: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin Course
- NSC86: Pembrolizumab + PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC88: Pembrolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC92: Lorlatinib
- NSC93: Larotrectinib
- NSC94: Entrectinib
- NSC97: Nivolumab + Ipilimumab
- NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
- NSC103: Atezolizumab
- NSC104: Nivolumab + Ipilimumab + PEMEtrexed/CARBOplatin
- NSC105: Nivolumab + Ipilimumab + PEMEtrexed/CISplatin
- NSC106: Nivolumab + Ipilimumab + PACLitaxel/CARBOplatin
- Emetic Risk has been updated on the following templates:
- NSC48: Albumin-bound PACLitaxel
- NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
- NSC102: Capmatinib
- Changes to the Chemotherapy Regimen section have been made on the following templates:
- NSC26: PEMEtrexed
- NSC41: CARBOplatin/Etoposide
- NSC43: PEMEtrexed/CISplatin
- NSC44: PACLitaxel/CARBOplatin + Bevacizumab
- NSC49: PEMEtrexed/CARBOplatin
- NSC52: PEMEtrexed/CARBOplatin with Concurrent Radiation
- NSC53: PEMEtrexed/CISplatin with Concurrent Radiation
- NSC55: PEMEtrexed/CARBOplatin + Bevacizumab
- NSC58: CISplatin/Etoposide with Concurrent Radiation
- NSC59: PEMEtrexed/CISplatin + Bevacizumab
- NSC62: Ramucirumab + DOCEtaxel
- NSC63: Nivolumab
- NSC64: Pembrolizumab
- NSC66: Osimertinib
- NSC74: PEMEtrexed/CISplatin
- NSC76: Pembrolizumab + PEMEtrexed/CARBOplatin
- NSC80: Durvalumab
- NSC83: PEMEtrexed/CARBOplatin
- NSC84: Pembrolizumab + PEMEtrexed/CISplatin
- NSC85a: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin Course
- NSC85b: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab Maintenance Course
- NSC86: Pembrolizumab + PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC88: Pembrolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
- NSC97: Nivolumab + Ipilimumab
- NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
- NSC103: Atezolizumab
- NSC104: Nivolumab + Ipilimumab + PEMEtrexed/CARBOplatin
- NSC105: Nivolumab + Ipilimumab + PEMEtrexed/CISplatin
- NSC106: Nivolumab + Ipilimumab + PACLitaxel/CARBOplatin
- The following note has been deleted from the Other Supportive Therapy section on the templates listed below:
- Risk of serious bacterial, viral, and fungal infections exists during treatment. Refer to drug package insert, individual NCCN disease guideline, and NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections for monitoring, prophylaxis, and/or preemptive therapy recommendations.
- NSC85a: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin Course
- NSC85b: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab Maintenance Course
- NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
- NSC103: Atezolizumab
- Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.